Concepedia

Mary Geck

MG

Statistics

Publications

21

Citations

2.1K

H-Index

18

Active since

1993

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Array BioPharma (United States)

Oak Ridge National Laboratory

Harvard University

Beth Israel Deaconess Medical Center

Mary Geck is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, natural sciences, and pharmacology.

ORCID

Top concepts

Publications per year

1993–2021

21

Publications

21

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 903 citations · Full text

, , +4

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Scott D. Seiwert, Steven W. Andrews, Yutong Jiang et al. · Antimicrobial Agents and Chemotherapy · 2008 · 173 citations · Full text

, , +14

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

Wylie S. Palmer, G. Poncet-Montange, Gang Liu et al. · Journal of Medicinal Chemistry · 2015 · 152 citations · Full text

, , +20

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Yutong Jiang, Steven W. Andrews, Kevin R. Condroski et al. · Journal of Medicinal Chemistry · 2013 · 139 citations · Full text

, , +17

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Michael Soth, Kang Le, Maria Emilia Di Francesco et al. · Journal of Medicinal Chemistry · 2020 · 88 citations · Full text

1–5 of 21